本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

再鼎医药

38.11
+1.574.30%
盘后38.690.5830+1.53%17:55 EDT
成交量:105.61万
成交额:4,006.47万
市值:41.34亿
市盈率:-15.37
高:38.45
开:37.51
低:37.19
收:36.54
数据加载中...
2024/05/09

重要事件披露

Form 8-K - Current report
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/27

重要事件披露

Form 8-K - Current report
2024/02/17

SEC问询函

Form CORRESP - Correspondence
2024/02/09

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/08

重要事件披露

Form 8-K - Current report
2024/02/08

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/01

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/01

SEC问询函

Form CORRESP - Correspondence